Ongoing Short Pressure in KRYS
Krystal Biotech (KRYS) continues to face significant short-selling pressure, having been flagged on the FINRA threshold list for 77 consecutive trading days. This sustained presence indicates that the stock has consistently maintained a high short-volume ratio, a key indicator of persistent bearish sentiment. With short interest at 13.7% of the float and a borrow fee of 0.3%, the stock remains a notable target for short sellers in the biotech sector.
Analyzing the Data
The 77-day streak on the threshold list is a clear signal of ongoing short-selling activity. While the borrow fee remains stable at 0.3%, the high short interest relative to the float suggests that a significant portion of the market is betting against the company's prospects. Investors should monitor the stock for any signs of a short squeeze, particularly given the high short interest and the duration of the short-selling pressure.
Key Takeaways
- KRYS has been on the FINRA threshold list for 77 days.
- Short interest is 13.7% of the float.
- Borrow fee is 0.3%.
- Sustained short volume indicates persistent bearish pressure.
The Bottom Line
Krystal Biotech's extended presence on the FINRA threshold list underscores the persistent short-selling pressure facing the stock, making it a key name to watch for those tracking bearish market trends.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.